Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation

• Published in: Leukemia Vol. 29; no. 4; pp. 783 - 787
• Main Authors: Kamel, S, Horton, L, Ysebaert, L, Levade, M, Burbury, K, Tan, S, Cole-Sinclair, M, Reynolds, J, Filshie, R, Schischka, S, Khot, A, Sandhu, S, Keating, M J, Nandurkar, H, Tam, C S
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.04.2015; Nature Publishing Group
• Subjects: 631/443/1338/1339; 631/67/1059/602; 631/67/1990/283/1895; 692/699/1541; 692/700/565/1436; Adenine - analogs & derivatives; Adenosine; Adenosine diphosphate; Adenosine Diphosphate - pharmacology; Aged; Aged, 80 and over; Agglomeration; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; ATPases; Bleeding; Blood Platelets - drug effects; Blood Platelets - pathology; Bruising; Bruton's tyrosine kinase; Cancer Research; Cells, Cultured; Chronic lymphocytic leukemia; Collagen; Collagen - pharmacology; Critical Care Medicine; Defects; Drug therapy; Enzyme inhibitors; Female; Gaging; Genetic aspects; Glycoprotein VI; Glycoproteins; Health aspects; Hematology; Hemorrhage - chemically induced; Hemorrhage - diagnosis; Hemorrhage - pathology; Humans; Ibrutinib; Inhibitor drugs; Intensive; Internal Medicine; Kinases; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - pathology; Light transmission; Lymphoma, Mantle-Cell - drug therapy; Lymphoma, Mantle-Cell - pathology; Male; Medicine; Medicine & Public Health; Middle Aged; Oncology; original-article; Patients; Physiological aspects; Piperidines; Platelet aggregation; Platelet Aggregation - drug effects; Protein-tyrosine kinase; Pyrazoles - administration & dosage; Pyrazoles - adverse effects; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Receiving; Severity of Illness Index; Tyrosine; Australia

The BTK (Bruton’s tyrosine kinase) inhibitor ibrutinib is associated with an increased risk of bleeding. A previous study reported defects in collagen- and adenosine diphosphate (ADP)-dependent platelet responses when ibrutinib was added ex vivo to patient samples. Whereas the collagen defect is exp...